<DOC>
	<DOC>NCT00277303</DOC>
	<brief_summary>This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with metastatic colorectal cancer (CRC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.</brief_summary>
	<brief_title>Study of XL999 in Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Males and females with histologically confirmed metastatic colorectal cancer Measurable disease according to Response Criteria for Solid Tumors (RECIST) At least 1 prior therapeutic regimen (chemotherapy or biologic) ECOG performance status of 0 or 1 Life expectancy ≥3 months Adequate organ and marrow function No other malignancies within 5 years Signed informed consent Radiation to ≥25% of bone marrow within 30 days of XL999 treatment Treatment with systemic anticancer therapy within 30 days of XL999 treatment Subject has not recovered to ≤ grade 1 or to within 10% of baseline from adverse events due to other medications administered &gt;30 days prior to study enrollment History of or known brain metastases, current spinal cord compression, or carcinomatous meningitis Uncontrolled and/or intercurrent illness Pregnant or breastfeeding females Known HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Colon Cancer</keyword>
</DOC>